Matthew Robbins, MD, author of “COVID-19 and headache: a primer for trainees,” details how care has changed for patients with chronic headaches in the midst of the COVID-19 pandemic.
The researchers compared anti-CGRP mAbs with other drugs for the prevention of episodic and chronic migraine using a likelihood to help versus harm analysis.
The researchers’ goal was to provide an overview of endpoints and outcomes in the current acute migraine clinical trial literature to facilitate the development of novel treatments.
The purpose of this study was to evaluate the subsequent health resource utilization (HRU) of patients with migraine who received opioid medications at ED visits.
The researchers aimed to report a case of arachnoiditis as a complication of epidural blood patch (EBP) procedures and to systematically review the diagnostic workup, clinical outcomes, and treatment modalities reported in the literature.
Study investigators sought to determine if galcanezumab would reduce not only the frequency of migraine days but also the disabling nonpain symptoms of episodic and chronic migraine.
